Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Tumorablative haploidentical hematopoietic cell transplantation for treatment of hematologic malignancy in children

Bone Marrow Transplantation volume 51, pages 587–588 (2016)Cite this article

Subjects

Allogeneic hematopoietic cell transplantation (HCT) is the curative therapy for patients with malignant hematologic diseases. However, for the patients with high risk or relapse, the 3-year overall survival (OS) rates were only about 20% for AML and 15% for ALL after myeloablative HCT.1, 2 HLA haploidentical HCT (Haplo-HCT) has become an effective alternative to treat those patients who lack a suitable HLA matched donor in China, however, relapse and severe GvHD are still major causes of mortality in Haplo-HSCT.3 Previously, we proposed a new concept of tumorablative allogeneic HCT (TAHCT) and used it to treat the adult leukemia at high risk or in relapse. The preliminary results have demonstrated that it reduced the relapse to about 20% in these patients.4, 5 Here we report the results of using TAHCT to treat the children patients with high-risk or relapsed hematologic malignancies.

Twenty-six patients aged median 7-year-old (range, 1.2–14), including 14 males and 12 females, were enrolled. Seven patients had AML, 13 ALL, 2 non-Hodgkin lymphoma (NHL) (T- lymphoblastic lymphoma (LBL)), and the other 3 myelodysplastic syndrome (MDS)/AML and 1 juvenile myelomonocytic leukemia with PTPN11 mutation. HLA for A, B, C, DRB1 and DQB1 was determined by high resolution DNA typing. Among 26 patient/donor pairs, 21 were mismatched in 5/10 HLA allele, 3 in 4/10 and 2 in 3/10 or 1/10.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Duval M, Klein JP, He WS, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730–3738.

    Article  Google Scholar 

  2. Wong R, Shahjahan M, Wang XM, Thall PF, de Lima M, Khoun I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108–114.

    Article  Google Scholar 

  3. Lu DP, Dong LJ, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  Google Scholar 

  4. Da WM, Wang JB, Zhang JP, Luo RM, Sun Y, Wei ZJ . Tumorablative tailored allogeneic hematopoietic stem cell transplantation in treatment of high risk and refractory leukemia. Chin J Exp Hematol 2009; 17: 219–220.

    Google Scholar 

  5. Da W-M, Da Y. Tumorablative allogeneic hematopoietic stem cell transplantation in the treatment of high-risk and refractory leukemia—new concepts and clinical practice. In: Demirer T (ed). Innovations in Stem Cell Transplantation. INTECH Publisher, Croatia 2013, pp 257–271.

  6. Lu DP . Hematopoietic stem cell transplantation. J Peking Univ 2009; 41: 255–258.

    Google Scholar 

  7. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437–3446.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology Oncology, Beijing Military General Hospital of PLA, Beijing, China

    R M Luo, W M Da, X M Zhang, Z L Du, Y J Si, Y Wang, Y Yue, W Chen, B Hu, G S Xing & Z C Feng

  2. Department of Hematology, General Hospital of CPLA, Beijing, China,

    W M Da

Authors
  1. R M Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W M Da
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X M Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z L Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y J Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G S Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Z C Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W M Da.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, R., Da, W., Zhang, X. et al. Tumorablative haploidentical hematopoietic cell transplantation for treatment of hematologic malignancy in children. Bone Marrow Transplant 51, 587–588 (2016). https://doi.org/10.1038/bmt.2015.260

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.260

Search

Advanced search

Quick links